GB1584080A - Absorbable hemostatic composition - Google Patents

Absorbable hemostatic composition Download PDF

Info

Publication number
GB1584080A
GB1584080A GB5050377A GB5050377A GB1584080A GB 1584080 A GB1584080 A GB 1584080A GB 5050377 A GB5050377 A GB 5050377A GB 5050377 A GB5050377 A GB 5050377A GB 1584080 A GB1584080 A GB 1584080A
Authority
GB
Grant status
Application
Patent type
Prior art keywords
composition
bone
powder
hemostatic
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB5050377A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ethicon Inc
Original Assignee
Ethicon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/10Polypeptides; Proteins
    • A61L24/106Fibrin; Fibrinogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/043Mixtures of macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005The prosthesis being constructed from a particular material
    • A61F2310/00365Proteins; Polypeptides; Degradation products thereof
    • A61F2310/00377Fibrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2400/00Materials characterised by their function or physical properties
    • A61L2400/04Materials for stopping bleeding
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2430/00Materials or treatment for tissue regeneration
    • A61L2430/02Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Description

(54) ABSORBABLE HEMOSTATIC COMPOSITION (71) We, ESICON, INC., a Corporation -organised under: the laws of the State of New. Jersey, United States of America, of Somerville, New Jersey,. United 'States of America, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement: This invention relates to a bone sealant, and more particularly, to an absorbable, semisolid composition for the control of osseous hemorrhage.

Various substances and compositions have been imployed by members of the medical profession to control the bleeding from cut bone surfaces. One class of materials used for the control of this type of hemorrhage is called bone wax. Bone waxes are used for the purpose of controlling hemorrhages from the cut surfaces of bones, such as those of the skull, by forcibly smearing the wax over the cut surface so that the rna- trial. acts mechanically to occlude and seal the open ends of the bleeding osseous vessels and sinuses.

Bone waxes used in surgery today are generally prepared from refined beeswax which has been admixed with other nonabsorbable and water insoluble - hydrocar- bons and vegetable oils. Certain disadvantages inhere in these bone wax compositions, as for example, relatively poor adhesion properties, separation of wax com ponents and - the hard, brittle state of the wax at room temperatures requiring use at elevated temperatures.

U.S. Patent No. 3,395,217 discloses nonabsorbable bone wax compositions comprised of low molecular weight ethylene copolymer waxes containing from about 15 to about 40 percent by weight of another unsaturated constituent affd having molecular weights in the range of 1000 to 4000.

These waxes have a semisolid consistency such that they can be kneaded between the fingers when at room temperature and have the right amount of tack and adhesion so that they can be easily manipulated in the hands of the surgeon or applied by any suitable applicator such as a gloved finger, spatula or appropriate disposable applicator.

Absorbable bone waxes have also been suggested. U.S. Patent No. 20772,999 describes a bone wax comprised of a water Soluble innocuous base and free acid cellulose glycolic acid ether or free acid cellulose hydroxypropionic acid ether as a hemostatic agent. The composition also preferably contains a tackifier such as cellulose glycolic acid ether salt or cellulose hydroxypropionic acid ether salt (preferably sodium salt) and water as a plasticizer.

The Annals of Surgery 132, 1128 (1950) describes an absobable hemostatic bone wax containing powdered oxidized cellulose as the hemostatic agent in a base of polyethylene glycol. The base is a mixture of high and low molecular weight polyethylene glycols selected to provide the malleability and consistency of material desired for this application.

The present invention provides a new absorbable bone sealant which is a putty-like semisolid at room temperature. The softness of the composition allows the material to be packaged in a syringe, plastic or coated paper envelope, or aluminum or glass tube from which it may be extruded or dispensed in desired amounts during use.

The sealant has sufficient tack so that it adheres to bone surfaces, yet is easily manipulated in the hands of the surgeon without crumbling or sticking to the surgeon's glovers.

- Absorbable bone sealant compositions of the present invention comprise a mixture of from 10 to 50 percent by weight of the total composition of a hemostatic powder in a water-soluble bicompatible base, optionally containing a small amount of tackifying agent, the hemostatic powder comprising a mixture of fibrin and collagen powders, preferably in substantially equal proportions. The base is preferably a mixture of water and a poly-ol such as glycerol, and the tackifying agent, if present, is preferably a polyglucoside such as dextran.

The sealant is formulated t6 the consist ency of a semisolid which is extrudable from a large orifice syringe. The composition is packaged in a syringe, plastic envelope, or aluminum tube and sterilized by radiation. During use, small amounts of the sealant may be extruded from the package as required by the surgeon. The composition is effective to control osseous hemorrhage from cut bone and does not interfer with subsequent healing and rejoining of bone parts.

It is desirable that the hemostatic compositions of the present invention, which comprise a mixture of a hemostatic powder, an innocuous absorbable base, and, preferably, a tackifying agent, should be formulated to obtain a semisolid material which may be readily spread upon the surface of cut bone in order to arrest the flow of blood.

Fibrin powder useful in the present invention may be obtained from human or animal blood according to the method disclosed in U.S. Patent No. 3,523,807. The fibrin powder is preferably reduced to a particle size of 500 microns or smaller, and most preferably to a size of about 200 microns. The fibrin powder thus obtained comprises, together with the collagen powder, from 10 to 50 percent by weight of the total hemostatic composition.

Collagen powder, useful in the present invention, is a finely divided, fluffy material which may be prepared according to the method disclosed in U.S. Patent No.

3,742,955. The collagen powder is preferably reduced to a particle size of 2 mm or less, and most preferably to less than 1 mm.

The collagen powder and fibrin powder are preferably mixed in a ratio of 40-95 percent by weight fibrin, 5-60 percent by weight collagen, in order to obtain a final product having the desired characteristics of softness and malleability. In a particularly preferred composition of this invention, substantially equal proportions of fibrin and collagen powders are used with good results.

The base component of the hemostatic composition may be an aqueous solution of a single substance or a mixture of two or more water-soluble innocuous substances.

Substances suitable as bases include nonvolatile compatible poly-ol compounds such as glycerol, propylene glycol, polymerized low molecular weight aliphatic glycols such as polymerized ethylene glycol and low molecular weight ethers or esters of polyglycols such as the methyl, ethyl, or propyl ethers of polyethylene glycols and the acetic or propionic esters of polyethylene or polypropylene glycols. Glycerol and polyethylene glycols are the preferred base materials, and polymerized ethylene glycols having a molecular weight in the range of 200 to 4000 and a consistency varying from a liquid or low viscosity to that of a waxy solid may be found suitable. If desired, a polymerized ethylene glycol having a molecular weight of 100 to 4000 may be used in combination with a polymerized ethylene glycol having a molecular weight of 200 to 600.

In addition to the hemostatic agent and innocuous base, the bone wax composition may also contain a tackifier such as a polyglucoside, gelatin or collagen gel, polyvinyl pyrrolidone, cellulose ester or other derivative of cellulose such as oxidized cellulose, a water-soluble starch, or a sugar. A preferred polyglucoside is dextran while a preferred cellulose derivative is cellulose glycolic acid ether salt or cellulose hydroxypropionic acid ether salt, most preferably the sodium salt.

The powdered fibrin hemostatic material and tackifying agent, if present, should desirably be thoroughly dispersed in the aqueous base to provide a semisolid composition which is readily spreadable on the surface of cut bone. The desired consistency of the composition is obtained by proper selection of the base material and the amount of water admixed therewith.

The following examples are provided to further illustrate preferred embodiments of the present invention: EXAMPLE I A hemostatic composition was prepared by thoroughly dispersing the following materials in the indicated proportions: Hemostatic Agent Fibrin powder (200 microns) - 5 g Collagen powder (2 mm) - 175 g Tackifying Agent Dextran (MW 60,000-90,000) - 80 g Base Glycerol - 30'0 g Water - 270 g Total 100 g The composition had a semisolid, puttylike, slightly sticky consistency. When loaded in a 1 cc hypodermic syringe with the needle removed, the mixture was readily extruded through the 16 mm diameter opening of the syringe to form a ribbon of material ready for use.

EXAMPLE II An extruded ribbon, 10 mm in length by 16 mm in diameter of the hemostatic composition of Example I was implanted in the lumbar muscles of 12 CFY strain rats weighing 250-300 kg. Two rats were sacrificed after 3, 7, 14, 28, 49, and 70 days, and the implant sites examined to determine absorption rates and tissue reaction to the bone sealant. The bone sealant was substantially completely absorbed by the 14th day with only few remnants of collagen being detectable. No trace of the sealant was found after 28 days. No abnormal tissue reaction was observed during the test.

EXAMPLE Ill Fourteen white male CFY rats, weighing 200-250 g, were anesthetized, and under surgically sterile conditions, the frontal and parietal bones of the skull were exposed.

Four holes were made, one in each quadrant of the skull, using a 2 mm burr on an electric drill. The parietal hole on one side was filled with a complete plug of the bone sealant of Example I, and the parietal hole on the other side plugged with a commercial bone wax control. One frontal hole was treated by spreading a small amount of the bone sealant of Example I on the cut surface, while the other hole was similarly treated with the bone wax control.

After 14 days, 12 rats were sacrificed and the wounds examined to determine the histological effects of the bone sealant and bone wax. The remaining 2 rats were sacrified and examined after 28 days. The following results were noted with no significant differences between the 14- and 28-day examination periods.

A. Bone Sealant of Example I i. Plugged holes. Holes filled with tis sue and bony edges lined with a layer of osteoblasts. There was consider able evidence of new bone formation in the area.

ii. Smeared holes. Similar to plugged holes, but connective tissue depressed below the level of the skull surface.

B. Bone Wax Control i. Plugged holes. Holes remained filled with a solid plug of wax which was easily removed. Hole was thickly roofed by connective tissue with evi dence of a much thinner tissue floor.

There was no indication of any signi ficant tissue activity in plug area.

ii. Smeared holes. Generally filled with connective tissue, but with fragments of wax visible in many cases.

The composition of Example I is a specific illustration of a generally preferred hemostatic composition having the following range of formulation: Fibrin powder - 15-25% Collagen powder - 15-25% Dextran - 5-10% Glycerol - 2040% Water 20-30% The precise composition illustrated in Example I was selected from the above general formulation to provide a desirable combination of properties, particularly consistency and adhesion or tack. Optimum formulations may vary somewhat from that given in Example I depending upon the particular properties of the individual in- gradients.

WHAT WE CLAIM IS: - 1. An absorbable hemostatic composition for use in the control of osseous hemorrhage comprising from 10 to 50 percent by weight of the total composition of a hemostatic powder in a water-soluble, biocompatible base, said hemostatic powder comprising a mixture of fibrin and collagen powders.

2. The composition of Claim 1 wherein the particle size of the fibrin powder is less than about 500 microns, and the particle size of the collagen powder is less than -about 2 mm.

3. The composition of Claim 1 wherein said biocompatible base comprises a mixture of water and a poly-ol.

4. The composition of Claim 3 wherein said poly-ol is selected from the group consisting of glycerol, propylene glycol, low molecular weight poly(alkylene) glycols, and low molecular weight ethers or esters of poly(alykylene) glycols.

5. The composition of Claim 3 wherein the poly-ol is glycerol and the ratio of glycerol to water is from 2:1 to 1: 2.

6. A composition of Claim 1 comprising, in addition to the hemostatic powder and base, a tackifier.

7. A composition of Claim 6 wherein the tackifier is selected from the group consisting of polyglucosides, gelatin, collagen gels, polyvinyl pyrrolidone, cellulose esters, oxidized cellulose, water-soluble starches, and sugars.

8. A composition of Claim 7 wherein the tackifier is dextran.

9. A composition of Claim 8 wherein the dextran is present in an amount of from 5 to 10 percent by weight of the composition.

10. A composition of Claim 1 wherein the hemostatic powder comprises from 40 to 95 percent by weight fibrin powder and from 5 to 60 percent by weight collagen powder.

11. An absorbable hemostatic composition for use in the control of osseous hemorrhage comprising, by weight, 15-25% fibrin powder 15-25to collagen powder 5 -10% dextran 2040% glycerol 20-30% water.

12. The composition of Claim 11 where

**WARNING** end of DESC field may overlap start of CLMS **.

Claims (14)

**WARNING** start of CLMS field may overlap end of DESC **. the implant sites examined to determine absorption rates and tissue reaction to the bone sealant. The bone sealant was substantially completely absorbed by the 14th day with only few remnants of collagen being detectable. No trace of the sealant was found after 28 days. No abnormal tissue reaction was observed during the test. EXAMPLE Ill Fourteen white male CFY rats, weighing 200-250 g, were anesthetized, and under surgically sterile conditions, the frontal and parietal bones of the skull were exposed. Four holes were made, one in each quadrant of the skull, using a 2 mm burr on an electric drill. The parietal hole on one side was filled with a complete plug of the bone sealant of Example I, and the parietal hole on the other side plugged with a commercial bone wax control. One frontal hole was treated by spreading a small amount of the bone sealant of Example I on the cut surface, while the other hole was similarly treated with the bone wax control. After 14 days, 12 rats were sacrificed and the wounds examined to determine the histological effects of the bone sealant and bone wax. The remaining 2 rats were sacrified and examined after 28 days. The following results were noted with no significant differences between the 14- and 28-day examination periods. A. Bone Sealant of Example I i. Plugged holes. Holes filled with tis sue and bony edges lined with a layer of osteoblasts. There was consider able evidence of new bone formation in the area. ii. Smeared holes. Similar to plugged holes, but connective tissue depressed below the level of the skull surface. B. Bone Wax Control i. Plugged holes. Holes remained filled with a solid plug of wax which was easily removed. Hole was thickly roofed by connective tissue with evi dence of a much thinner tissue floor. There was no indication of any signi ficant tissue activity in plug area. ii. Smeared holes. Generally filled with connective tissue, but with fragments of wax visible in many cases. The composition of Example I is a specific illustration of a generally preferred hemostatic composition having the following range of formulation: Fibrin powder - 15-25% Collagen powder - 15-25% Dextran - 5-10% Glycerol - 2040% Water 20-30% The precise composition illustrated in Example I was selected from the above general formulation to provide a desirable combination of properties, particularly consistency and adhesion or tack. Optimum formulations may vary somewhat from that given in Example I depending upon the particular properties of the individual in- gradients. WHAT WE CLAIM IS: -
1. An absorbable hemostatic composition for use in the control of osseous hemorrhage comprising from 10 to 50 percent by weight of the total composition of a hemostatic powder in a water-soluble, biocompatible base, said hemostatic powder comprising a mixture of fibrin and collagen powders.
2. The composition of Claim 1 wherein the particle size of the fibrin powder is less than about 500 microns, and the particle size of the collagen powder is less than -about 2 mm.
3. The composition of Claim 1 wherein said biocompatible base comprises a mixture of water and a poly-ol.
4. The composition of Claim 3 wherein said poly-ol is selected from the group consisting of glycerol, propylene glycol, low molecular weight poly(alkylene) glycols, and low molecular weight ethers or esters of poly(alykylene) glycols.
5. The composition of Claim 3 wherein the poly-ol is glycerol and the ratio of glycerol to water is from 2:1 to 1: 2.
6. A composition of Claim 1 comprising, in addition to the hemostatic powder and base, a tackifier.
7. A composition of Claim 6 wherein the tackifier is selected from the group consisting of polyglucosides, gelatin, collagen gels, polyvinyl pyrrolidone, cellulose esters, oxidized cellulose, water-soluble starches, and sugars.
8. A composition of Claim 7 wherein the tackifier is dextran.
9. A composition of Claim 8 wherein the dextran is present in an amount of from 5 to 10 percent by weight of the composition.
10. A composition of Claim 1 wherein the hemostatic powder comprises from 40 to 95 percent by weight fibrin powder and from 5 to 60 percent by weight collagen powder.
11. An absorbable hemostatic composition for use in the control of osseous hemorrhage comprising, by weight, 15-25% fibrin powder 15-25to collagen powder 5 -10% dextran 2040% glycerol 20-30% water.
12. The composition of Claim 11 where
in the particle size of the fibrin powder is less than about 500 microns and the particle size of the collagen powder is less than about 2 mm.
13. The composition of Claim 11 wherein the molecular weight of the dextran is in the range of from 60,000 to 90,000.
14. A hemostatic composition as claimed in any of Claims l fo 13 and sub: stantially as described in the foregoing Examples.
GB5050377A 1977-12-05 1977-12-05 Absorbable hemostatic composition Expired GB1584080A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB5050377A GB1584080A (en) 1977-12-05 1977-12-05 Absorbable hemostatic composition

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB5050377A GB1584080A (en) 1977-12-05 1977-12-05 Absorbable hemostatic composition
CA 314424 CA1119515A (en) 1977-12-05 1978-10-26 Absorbable hemostatic composition
FR7832651A FR2410477B1 (en) 1977-12-05 1978-11-20
DE19782852319 DE2852319C2 (en) 1977-12-05 1978-12-04

Publications (1)

Publication Number Publication Date
GB1584080A true true GB1584080A (en) 1981-02-04

Family

ID=10456141

Family Applications (1)

Application Number Title Priority Date Filing Date
GB5050377A Expired GB1584080A (en) 1977-12-05 1977-12-05 Absorbable hemostatic composition

Country Status (4)

Country Link
CA (1) CA1119515A (en)
DE (1) DE2852319C2 (en)
FR (1) FR2410477B1 (en)
GB (1) GB1584080A (en)

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0086627A1 (en) * 1982-02-12 1983-08-24 Unitika Ltd. Anti-cancer device
US4439420A (en) * 1982-11-16 1984-03-27 Ethicon, Inc. Absorbable hemostatic composition
US4440789A (en) * 1982-11-16 1984-04-03 Ethicon, Inc. Synthetic absorbable hemostatic composition
US4443430A (en) * 1982-11-16 1984-04-17 Ethicon, Inc. Synthetic absorbable hemostatic agent
USRE32208E (en) * 1982-11-16 1986-07-15 Ethicon, Inc. Absorbable hemostatic composition
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
EP1010436A1 (en) * 1998-12-19 2000-06-21 MERCK PATENT GmbH Improved bone wax composition
US6117425A (en) * 1990-11-27 2000-09-12 The American National Red Cross Supplemented and unsupplemented tissue sealants, method of their production and use
US6174299B1 (en) 1991-09-09 2001-01-16 Harvey B. Pollard Method for treating hemophilia A and B and AIDS and devices used therein
US6197325B1 (en) 1990-11-27 2001-03-06 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6559119B1 (en) 1990-11-27 2003-05-06 Loyola University Of Chicago Method of preparing a tissue sealant-treated biomedical material
US6762336B1 (en) 1998-01-19 2004-07-13 The American National Red Cross Hemostatic sandwich bandage
WO2005053762A1 (en) * 2003-12-04 2005-06-16 Friedrich-Baur-Gmbh Bioresorbable material
WO2005072700A2 (en) * 2004-01-30 2005-08-11 Ferrosan A/S Haemostatic sprays and compositions
USRE39192E1 (en) * 1990-11-27 2006-07-18 American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
USRE39298E1 (en) * 1990-11-27 2006-09-19 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
USRE39321E1 (en) * 1990-11-27 2006-10-03 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US7189410B1 (en) 1990-11-27 2007-03-13 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US7196054B1 (en) 1990-11-27 2007-03-27 The American National Red Cross Methods for treating wound tissue and forming a supplemented fibrin matrix
WO2009081408A2 (en) * 2007-12-26 2009-07-02 Metamorefix Pulverized fibrin clots and pharmaceutical compositions containing them
US7923431B2 (en) 2001-12-21 2011-04-12 Ferrosan Medical Devices A/S Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis
US7955616B2 (en) 2003-09-23 2011-06-07 Orthocon, Inc. Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
US7955288B2 (en) 2002-12-11 2011-06-07 Ferrosan Medical Devices A/S Gelatine-based materials as swabs
US7989000B2 (en) 2003-09-23 2011-08-02 Orthocon, Inc. Absorbable putty-like implants and methods for their use for mechanical hemostasis of bone and for the treatment of osseous defects
US8021684B2 (en) 2004-07-09 2011-09-20 Ferrosan Medical Devices A/S Haemostatic composition comprising hyaluronic acid
US8092464B2 (en) 2005-04-30 2012-01-10 Warsaw Orthopedic, Inc. Syringe devices and methods useful for delivering osteogenic material
US8105628B2 (en) 2003-09-23 2012-01-31 Orthocon, Inc. Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
US8445009B2 (en) 2006-08-04 2013-05-21 Stb, Ltd Processes for the production of solid dressings for treating wounded tissue
US8506646B2 (en) 2005-04-29 2013-08-13 Warsaw Orthopedic, Inc. Multi-purpose medical implant devices
US8603528B2 (en) 2004-09-16 2013-12-10 Abyrx, Inc. Compositions and method for the reduction of post-operative pain
US8642831B2 (en) 2008-02-29 2014-02-04 Ferrosan Medical Devices A/S Device for promotion of hemostasis and/or wound healing
US8679528B2 (en) 2002-09-10 2014-03-25 American National Red Cross Hemostatic dressing
US9131929B2 (en) 2007-08-06 2015-09-15 Stb, Ltd. Methods and dressings for sealing internal injuries
US9265858B2 (en) 2012-06-12 2016-02-23 Ferrosan Medical Devices A/S Dry haemostatic composition
US9724078B2 (en) 2013-06-21 2017-08-08 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56501129A (en) * 1979-08-31 1981-08-13
DE2967060D1 (en) * 1979-12-18 1984-07-19 Oscobal Ag Bone replacement material and process for producing a bone replacement material
DE3014123C2 (en) * 1980-04-12 1982-03-18 B. Braun Melsungen Ag, 3508 Melsungen, De
DE3374659D1 (en) * 1983-02-03 1988-01-07 Ethicon Inc Paste for hemostasis and for temporary relief of defects in the traumatism of bones
EP0166263A1 (en) * 1984-05-31 1986-01-02 Green Cross Corporation Filler composition for filling in defect or hollow portion of bone and kit or set for the preparation of the filler composition
JPH0430927B2 (en) * 1984-11-19 1992-05-25
US4891359A (en) * 1988-12-08 1990-01-02 Johnson & Johnson Patient Care, Inc. Hemostatic collagen paste composition
GB9211432D0 (en) * 1992-05-29 1992-07-15 Jevco Ltd Absorbable bone sealant
US5696101A (en) * 1996-04-16 1997-12-09 Eastman Chemical Company Oxidized cellulose and vitamin E blend for topical hemostatic applications
US6117444A (en) * 1997-04-10 2000-09-12 Brigham & Women's Hospital Polyethylene glycol/microfibrillar collagen composite serves as a resorbable hemostatic agent
DE202010009512U1 (en) 2010-05-28 2011-01-13 Hfp Ingredients B.V. collagen powder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2772999A (en) * 1952-06-06 1956-12-04 Johnson & Johnson Hemostatic surgical compositions and dressings
FR1325128A (en) * 1962-03-26 1963-04-26 A process for preparing bioplastes used as resorbable implants
US3523807A (en) * 1966-11-25 1970-08-11 Mihaly Gerendas Method of making a cross-linked fibrin prosthesis
US3742955A (en) * 1970-09-29 1973-07-03 Fmc Corp Fibrous collagen derived product having hemostatic and wound binding properties
US4006220A (en) * 1975-06-04 1977-02-01 Gottlieb Sheldon K Compositions and methods useful for repairing depressed cutaneous scars

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0086627A1 (en) * 1982-02-12 1983-08-24 Unitika Ltd. Anti-cancer device
EP0086627B1 (en) * 1982-02-12 1985-08-28 Unitika Ltd. Anti-cancer device
US4439420A (en) * 1982-11-16 1984-03-27 Ethicon, Inc. Absorbable hemostatic composition
US4440789A (en) * 1982-11-16 1984-04-03 Ethicon, Inc. Synthetic absorbable hemostatic composition
US4443430A (en) * 1982-11-16 1984-04-17 Ethicon, Inc. Synthetic absorbable hemostatic agent
USRE32208E (en) * 1982-11-16 1986-07-15 Ethicon, Inc. Absorbable hemostatic composition
USRE39298E1 (en) * 1990-11-27 2006-09-19 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US7229959B1 (en) 1990-11-27 2007-06-12 The American National Red Cross Supplemented fibrin matrix delivery systems
US6117425A (en) * 1990-11-27 2000-09-12 The American National Red Cross Supplemented and unsupplemented tissue sealants, method of their production and use
USRE39321E1 (en) * 1990-11-27 2006-10-03 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6197325B1 (en) 1990-11-27 2001-03-06 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6559119B1 (en) 1990-11-27 2003-05-06 Loyola University Of Chicago Method of preparing a tissue sealant-treated biomedical material
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US7208179B1 (en) 1990-11-27 2007-04-24 The American National Red Cross Methods for treating disease and forming a supplemented fibrin matrix
US7196054B1 (en) 1990-11-27 2007-03-27 The American National Red Cross Methods for treating wound tissue and forming a supplemented fibrin matrix
US7189410B1 (en) 1990-11-27 2007-03-13 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
USRE39192E1 (en) * 1990-11-27 2006-07-18 American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6174299B1 (en) 1991-09-09 2001-01-16 Harvey B. Pollard Method for treating hemophilia A and B and AIDS and devices used therein
US6762336B1 (en) 1998-01-19 2004-07-13 The American National Red Cross Hemostatic sandwich bandage
EP1010436A1 (en) * 1998-12-19 2000-06-21 MERCK PATENT GmbH Improved bone wax composition
US8283320B2 (en) 2001-12-21 2012-10-09 Ferrosan Medical Devices A/S Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostasis
US7923431B2 (en) 2001-12-21 2011-04-12 Ferrosan Medical Devices A/S Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis
US8679528B2 (en) 2002-09-10 2014-03-25 American National Red Cross Hemostatic dressing
US7955288B2 (en) 2002-12-11 2011-06-07 Ferrosan Medical Devices A/S Gelatine-based materials as swabs
US8337879B2 (en) 2003-09-23 2012-12-25 Orthocon, Inc. Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
EP2462957A2 (en) 2003-09-23 2012-06-13 Orthocon Inc. Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
EP2462958A2 (en) 2003-09-23 2012-06-13 Orthocon Inc. Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
US8309131B2 (en) 2003-09-23 2012-11-13 Orthocon, Inc. Absorbable putty-like implants and methods for their use for mechanical hemostasis of bone and for the treatment of osseous defects
US7955616B2 (en) 2003-09-23 2011-06-07 Orthocon, Inc. Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
US8105628B2 (en) 2003-09-23 2012-01-31 Orthocon, Inc. Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
US7989000B2 (en) 2003-09-23 2011-08-02 Orthocon, Inc. Absorbable putty-like implants and methods for their use for mechanical hemostasis of bone and for the treatment of osseous defects
WO2005053762A1 (en) * 2003-12-04 2005-06-16 Friedrich-Baur-Gmbh Bioresorbable material
WO2005072700A3 (en) * 2004-01-30 2005-09-09 Ferrosan As Haemostatic sprays and compositions
WO2005072700A2 (en) * 2004-01-30 2005-08-11 Ferrosan A/S Haemostatic sprays and compositions
US7923031B2 (en) 2004-01-30 2011-04-12 Ferrosan Medical Devices A/S Haemostatic sprays and compositions
CN1921896B (en) 2004-01-30 2010-11-24 弗罗桑公司 Haemostatic sprays and compositions
US8021684B2 (en) 2004-07-09 2011-09-20 Ferrosan Medical Devices A/S Haemostatic composition comprising hyaluronic acid
US8603528B2 (en) 2004-09-16 2013-12-10 Abyrx, Inc. Compositions and method for the reduction of post-operative pain
US8506646B2 (en) 2005-04-29 2013-08-13 Warsaw Orthopedic, Inc. Multi-purpose medical implant devices
US8092464B2 (en) 2005-04-30 2012-01-10 Warsaw Orthopedic, Inc. Syringe devices and methods useful for delivering osteogenic material
US8445009B2 (en) 2006-08-04 2013-05-21 Stb, Ltd Processes for the production of solid dressings for treating wounded tissue
US9131929B2 (en) 2007-08-06 2015-09-15 Stb, Ltd. Methods and dressings for sealing internal injuries
WO2009081408A2 (en) * 2007-12-26 2009-07-02 Metamorefix Pulverized fibrin clots and pharmaceutical compositions containing them
WO2009081408A3 (en) * 2007-12-26 2010-05-20 Metamorefix Pulverized fibrin clots and pharmaceutical compositions containing them
US9533069B2 (en) 2008-02-29 2017-01-03 Ferrosan Medical Devices A/S Device for promotion of hemostasis and/or wound healing
US8642831B2 (en) 2008-02-29 2014-02-04 Ferrosan Medical Devices A/S Device for promotion of hemostasis and/or wound healing
US9999703B2 (en) 2012-06-12 2018-06-19 Ferrosan Medical Devices A/S Dry haemostatic composition
US9265858B2 (en) 2012-06-12 2016-02-23 Ferrosan Medical Devices A/S Dry haemostatic composition
US9724078B2 (en) 2013-06-21 2017-08-08 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same

Also Published As

Publication number Publication date Type
CA1119515A (en) 1982-03-09 grant
DE2852319C2 (en) 1990-08-16 grant
DE2852319A1 (en) 1979-06-07 application
FR2410477A1 (en) 1979-06-29 application
CA1119515A1 (en) grant
FR2410477B1 (en) 1981-11-13 grant

Similar Documents

Publication Publication Date Title
US3339546A (en) Bandage for adhering to moist surfaces
US4597960A (en) Microencapsulated astringent hemostatic agents and methods of use
US2155658A (en) Surgical and medical preparations
US5578661A (en) Gel forming system for use as wound dressings
US2804424A (en) Method of preparing a tetracycline type antibiotic-containing wound dressing
US5232702A (en) Silicone pressure sensitive adhesive compositons for transdermal drug delivery devices and related medical devices
US5814031A (en) Structured occllusive dressings
US5270358A (en) Composite of a disperesed gel in an adhesive matrix
US2804073A (en) Fluid surgical dressing
US4657592A (en) Root canal sealer
Finn et al. Osseous regeneration in the presence of four common hemostatic agents
US4310516A (en) Cosmetic and pharmaceutical vehicle thickened with solid emulsifier
US4141864A (en) Osseous cement composition
US4650665A (en) Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition
US6007613A (en) Bioadhesive; preparation procedure and device for the application of a bioadhesive; and hardeners for a bioadhesive
US6375977B1 (en) Hydrocolloid adhesive mass useful for medical purposes
US6849082B2 (en) Method for curing cyanoacrylate adhesives
US3767784A (en) Composition for the protection and treatment of injured body tissue and method of utilizing the same
US4956350A (en) Wound filling compositions
US6568398B2 (en) Method for hemostasis
US6146654A (en) Adhesive medical composition with sustained medicament releasbility and process for preparing same
US4594240A (en) Sheet-shape adhesive preparation
US6583220B1 (en) Biological fluid absorbing pressure sensitive adhesives
US5214093A (en) Adhesive formulation for nonsurgical blepheroplasty
Blackman et al. An evaluation of the biocompatibility of a glass lonomer-silver cement in rat connective tissue

Legal Events

Date Code Title Description
PS Patent sealed
704A Declaration that licence is not available as of right for an excepted use (par. 4a/1977)
PE20 Patent expired after termination of 20 years

Effective date: 19971204